AccessibilityHelp
MDxHealth logo

MDxHealth(NASDAQ) MDXH

Market Cap$17.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2009)-100%
5 Year-99%
1 Year-96%
1 Month-70%
$0.18
-0.38%
-0.00Today
MDxHealth last closing stock price
MetricPriceDate
Last closeUSD 0.182026-10-23
MDxHealth stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-11.28%USD 0.212026-10-16
1 month-69.73%USD 0.612026-09-23
3 month-55.29%USD 0.412026-07-24
Year to date-94.87%USD 3.572025-12-31
1 year-95.83%USD 4.402025-10-23
3 year-92.67%USD 2.502023-10-17
5 year-98.76%USD 14.802021-10-04
Since inception-99.79%USD 87.502009-06-15

MDxHealth Financials at a Glance

Market Cap

$17.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$156.54M

Net Income (TTM)

-$55.71M

EPS (TTM)

-$0.73

P/E Ratio

-0.25

Dividend

$0.00

Beta (Volatility)

13310.59 (High)

Price

$0.18

Volume

656,461

Open

$0.19

Previous Close

$0.18

Daily Range

$0.18 - $0.19

52-Week Range

$0.17 - $5.33

Estimated Earnings Date

Aug 13, 2026

MDXH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MDxHealth

MDxHealth S.A. is a commercial-stage precision diagnostics firm specializing in urologic solutions globally. The company offers innovative genomic testing for prostate cancer, aiming to enhance patient outcomes while reducing the need for invasive procedures.

Products and Services
  • SelectMDx: A non-invasive urine test for prostate cancer detection
  • ConfirmMDx: An epigenetic diagnostic tool for confirming prostate cancer
  • Comprehensive support services for healthcare professionals and patients
Growth Outlook
  • Revenue of $27.2 million reported in Q2 2026, showing strong market demand
  • Consistent growth in gross profit margin, reaching 65.7% in Q2 2026
  • Expansion into new markets across Europe and the U.S. enhances growth potential
Financial Highlights
  • Trailing twelve months (TTM) revenue of $54.7 million, indicating robust sales performance
  • Operating loss reduced to $5.1 million in Q2 2026, reflecting improved operational efficiency
  • Cash and cash equivalents of $19.2 million as of June 2026, providing liquidity for growth initiatives
MDxHealth S.A. operates in the medical diagnostics and research sector, focusing on precision medicine for prostate cancer. The company's flagship products, SelectMDx and ConfirmMDx, leverage advanced genomic technologies to provide accurate diagnostic solutions. This approach not only aids in early detection but also minimizes the risks associated with invasive procedures. The growth outlook for MDxHealth appears promising, with a notable increase in revenue and gross profit margins. The company has successfully expanded its market presence, particularly in the U.S. and various European countries, which positions it well for future growth. Recent financial performance indicates a commitment to improving operational efficiency, as evidenced by the reduction in operating losses. Investors may find MDxHealth's innovative approach to prostate cancer diagnostics and its strategic market expansion appealing. The company's financial health, characterized by a solid cash position and increasing revenue, suggests a potential for sustained growth in the evolving healthcare landscape.
AI Generated • Oct 19, 2026

Industry

Biotechnology

Sector

Health Care

Employees

364

CEO

Michael K. McGarrity

Website

www.mdxhealth.com

Headquarters

Herstal, WA 4040, BE

MDXH Financials

Key Financial Metrics (TTM)

Gross Margin

57.64%

Operating Margin

-20.36%

Net Income Margin

-37.02%

Return on Equity

142.63%

Return on Capital

-18.55%

Return on Assets

-22.94%

Earnings Yield

-4.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$17.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

95.42M

Volume

656.46K

Avg. Volume

6.05M

Financials (TTM)

Gross Profit

$94.56M

Operating Income

-$29.28M

EBITDA

-$13.14M

Operating Cash Flow

-$15.80M

Capital Expenditure

-$859.00K

Free Cash Flow

-$16.66M

Cash & ST Invst.

$19.21M

Total Debt

$105.85M

MDxHealth Performance Analysis

MDxHealth annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 37,054,00066.6%
20232023-12-31USD 70,193,00089.4%
20242024-12-31USD 90,049,00028.3%
20252025-12-31USD 107,875,00019.8%
MDxHealth sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3114.4%
Q22025-06-30-44.6%
Q42025-12-31105.5%
Q22026-06-30-50.2%
MDxHealth annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.7816.7%
20232023-12-31USD -1.66-40.1%
20242024-12-31USD -1.16-30.4%
20252025-12-31USD -0.67-42.1%
MDxHealth sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3147.9%
Q22025-06-3021.1%
Q42025-12-31-23.3%
Q22026-06-3040.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$27.21M

-35.2%

Gross Profit

$17.89M

-29.4%

Gross Margin

65.75%

N/A

Market Cap

$17.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$48.05K

N/A

Employees

364

N/A

Net Income

-$11.53M

+42.5%

EBITDA

-$1.01M

+88.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$19.21M

-10.0%

Total Debt

$105.85M

+86.8%

Accounts Receivable

$14.93M

+10.9%

Inventory

$6.43M

+71.4%

Long Term Debt

$104.04M

+91.2%

Short Term Debt

$1.80M

-20.0%

Return on Assets

-22.94%

N/A

Return on Invested Capital

-17.60%

N/A

Free Cash Flow

-$5.89M

+49.0%

Operating Cash Flow

-$5.85M

+40.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SNWVSANUWAVE Health Inc.
$5.22-1.51%
QTRXQuanterix Corporation
$2.86+0.70%
XGNExagen Inc.
$7.27-2.81%
IMRXImmuneering Corporation
$3.73-2.10%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$147.49+1.89%
TAT&T
$20.93-7.96%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$83.56+1.77%
NUNu Holdings
$15.16+2.92%

Questions About MDXH

What is the current price of MDxHealth?

MDxHealth is trading at $0.18 per share.

What is the 52-week range for MDxHealth?

Over the past 52 weeks, MDxHealth has traded between $0.17 and $5.33.

How much debt does MDxHealth have?

As of the most recent reporting period, MDxHealth reported total debt of $105.85M.

How much cash does MDxHealth have on hand?

MDxHealth reported $19.21M in cash and cash equivalents in its most recent financial results.

What is MDxHealth’s dividend yield?

MDxHealth does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services